CMPS is trading at $12.00 (7.6% down) as investors continue to react to six-month durability results from its COMP006 Phase 3 trial in treatment-resistant depression.
- While the data demonstrated rapid and durable efficacy and a generally well-tolerated safety profile, the stock fell as the market scrutinized response rates and long-term assumptions.
- The downward move extends Tuesday’s post-headline decline into pre-market trading following the July 7, 2026, data release.